Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Valero

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancerA U Buzdar, S E Singletary, R L Theriault, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancerM Ayers, W F Symmans, J Stec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancerV Valero, S E Jones, D D Von Hoff, et al.
Journal of Cancer|June 22, 2016
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast CancerM Mego, H Gao, E N Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypesH Masuda, T M Brewer, D D Liu, et al.
Endocrine-Related Cancer|December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeedingW F Symmans, D J Fiterman, S K Anderson, et al.
NPJ Breast Cancer|December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activityJ K Litton, M Scoggins, D L Ramirez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancerR Bruno, D Hille, A Riva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationA D Seidman, M N Fornier, F J Esteva, et al.
ESMO Open|November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆A S Raghavendra, D B Zakon, Q Jin, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancerA U Buzdar, S E Singletary, R L Theriault, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancerM Ayers, W F Symmans, J Stec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancerV Valero, S E Jones, D D Von Hoff, et al.
Journal of Cancer|June 22, 2016
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast CancerM Mego, H Gao, E N Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypesH Masuda, T M Brewer, D D Liu, et al.
Endocrine-Related Cancer|December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeedingW F Symmans, D J Fiterman, S K Anderson, et al.
NPJ Breast Cancer|December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activityJ K Litton, M Scoggins, D L Ramirez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancerR Bruno, D Hille, A Riva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationA D Seidman, M N Fornier, F J Esteva, et al.
ESMO Open|November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆A S Raghavendra, D B Zakon, Q Jin, et al.
Pageof 12